Management of painful diabetic neuropathy: Guideline guidance or jungle?

Current Diabetes Reports

Volumn 12, Issue 4, 2012, Pages 403-413

  Spallone, Vincenza ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antidepressants; Diabetic neuropathy; Duloxetine; Gabapentin; Guidelines; Neuropathic pain; Opioids; Oxycodone; Painful neuropathy; Pregabalin; SNRI; Tramadol; Treatment; Venlafaxine

Indexed keywords

ANALGESIA; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; NEUROPATHIC PAIN; PAIN ASSESSMENT; PATIENT MONITORING; PATIENT PARTICIPATION; PATIENT SAFETY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; REVIEW; TREATMENT PLANNING;

DIABETIC NEUROPATHIES; EVIDENCE-BASED PRACTICE; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; NEURALGIA; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84865596036     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0287-2     Document Type: Review

References (86)

1. Davies M, Brophy S, Williams R, et al. The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-22. (Pubitemid 44127574)
2. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35:206-13.
3. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: Consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629-38. This paper is a detailed report of the sub-committee on Painful Diabetic Neuropathy of the Toronto Expert Panel. The International Consensus Workshop in Toronto in 2009 produced evidence-based guidelines on different aspects of diabetic neuropathy.
4. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev. 2011;7:208-20. This paper is a comprehensive review on contemporary issues in diabetic polyneuropathy.
5. Spallone V, Lacerenza M, Rossi A, et al. Painful diabetic polyneuropathy: Approach to diagnosis and management. Clin J Pain 2011 Dec 30. [Epub ahead of print] This paper provides a current practical overview of the diagnostic workup and management of PDPN.
6. Gore M, Dukes E, Rowbotham DJ, Tai KS, Leslie D. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain. 2007;11:652-64. (Pubitemid 46818059)
7. O'Connor AB. Neuropathic pain. Quality of life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27:95-112.
8. Grol R. Has guideline development gone astray? Yes. BMJ. 2010;340:c306. This is the first interesting part of a brief debate on the value of guidelines in clinical practice.
9. Gibbons RJ, Antman EM, Smith SC. Has guideline development gone astray? No. BMJ. 2010;340:c343. This is the second interesting part of a brief debate on the value of guidelines in clinical practice.
10. Getchius TS, Moses LK, French J, et al. AAN guidelines: A benefit to the neurologist. Neurology. 2010;75:1126-7.
11. International Diabetes Federation Clinical Guidelines Task Force. Guide for Guidelines. A guide for clinical guideline development. Available at www.idf.org. Accessed April 2012
12. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
13. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007;132:237-51. (Pubitemid 350051570)
14. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3-S14. This paper reviews and updates the 2007 NeuPSIG guidelines on the management of neuropathic pain of different etiology. It provides both brief overview of recent studies and practical advice for a stepwise approach to the patient with neuropathic pain.
15. CEBM Centre for Evidence-based Medicine. CEBM Web site. Levels of evidence and grades of recommendation. Available at http://www.cebm.net/index. aspx?o01025. Accessed April 2012
16. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153-69. (Pubitemid 44581463)
17. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88. This paper updates the 2006 EFNS guidelines on pharmacological treatment of neuropathic pain. Appendix 1 contains summary data of the studies published from 2005 and included in the systematic review.
18. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14:952-70. (Pubitemid 47300786)
19. BraininM, BarnesM, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces -revised recommendations 2004. Eur J Neurol. 2004;11:577-81. (Pubitemid 39279947)
20. Gilron I, Bailey JM, Tu D. Holden RRet al: Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised controlled crossover trial. Lancet. 2009;374:1252-61.
21. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology. 2007;68:1178-82. (Pubitemid 46608464)
22. AAN (American Academy of Neurology). Clinical Practice Guideline Process Manual. 2004th ed. St. Paul: The American Academy of Neurology; 2004.
23. AAN (American Academy of Neurology). Clinical Practice Guideline Process Manual. 2011th ed. St. Paul: The American Academy of Neurology; 2011.
24. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;3: CD007076.
25. Landefeld CS, Steinman MA. The Neurontin legacy -marketing through misinformation and manipulation. N Engl J Med. 2009;360:103-6.
26. National Institute for Health and Clinical Excellence. Neuropathic pain. The pharmacologicalmanagement of neuropathic pain in adults in non-specialist settings. NICE clinical guideline 96. Issued: March 2010. Available at: Www.nice.org.uk/guidance/CG96. Accessed April 2012. This NICE guideline on the pharmacological management of neuropathic pain provides evidence-based data on efficacy, safety and cost-effectiveness of the available drugs for neuropathic pain. It gives a thorough stepwise care pathway for clinicians and patients.
27. National Institute for Health and Clinical Excellence. Type 1 diabetes: Diagnosis and management of type 1 diabetes in children, young people and adults (NICE clinical guideline 15). Issued: July 2004. Available at http://www.nice.org.uk/guidance/index.jsp? action0byID&o010944. Accessed April 2012
28. National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes (NICE clinical guideline 87). Issued: May 2009. Available at http://www.nice.org.uk/guidance/index. jsp? action0byID&o012165. Accessed April 2012
29. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-21. (Pubitemid 351147828)
30. Fox-Rushby JA, GL Griffith, JR Ross et al. The clinical and costeffectiveness of different treatment pathways for neuropathic pain [NP]. NIHR Health Technology Assessment (HTA) programme, ref. 05/30/03. In press. Project abstract available from www.hta.ac.uk/ 1527. Accessed April 2012
31. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758-65. This paper is the AAN guideline on the pharmacological treatment of PDPN prepared according to AAN guideline rules. It contains evidence-based recommendations on the efficacy on pain and quality of life of available treatments.
32. Tesfaye S, Boulton AJ, Dyck PJ, et al. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-93. This paper is the preliminary summary report of the Toronto consensus meeting on diabetic neuropathy. It provides novel insights into definition and diagnosis of different forms of diabetic neuropathy.
33. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: A reversible painful autonomic neuropathy. Ann Neurol. 2010;67:534-41.
34. Hartemann A, Attal N, Bouhassira D, et al. Painful diabetic neuropathy: Diagnosis and management. Diabetes Metab. 2011;37:377-88. This paper is the result of a consensus work developed under the auspices of the French-speaking Society of Diabetology. It gives a practical and lucid approach to both diagnosis and treatment of PDPN.
35. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007; (4):CD005454.
36. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011; (3):CD007938.
37. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009; (4):CD007115.
38. Duehmke RM, Hollingshead J, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev. 2006; (3):CD003726.
39. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011; (10):CD009183.
40. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2009; (4):CD007393.
41. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12. (Pubitemid 26120810)
42. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: Treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81(4 Suppl):S12-25.
43. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain -consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13-21. (Pubitemid 46744774)
44. Bohlega S, Alsaadi T, Amir A, et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: Expert panel recommendations for the middle East region. J Int Med Res. 2010;38:295-317. This paper contains guidelines on diagnosis and managenement of neuropathic pain developed by an expert panel of Middle East region. It has a clinical perspective and pays attention to the needs of that region.
45. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes. Edinburgh: SIGN; 2010. (SIGN publication no.116). Available at http://www.sign.ac.uk/guidelines/fulltext/116/index. html Accessed April 2012
46. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. End Pract. 2011;17:1-51.
47. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-6. (Pubitemid 28283262)
48. Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications. 2008;22:241-5. (Pubitemid 351885487)
49. Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71-8. (Pubitemid 37162475)
50. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: Relationship to study characteristics. Neurology. 2008;70:263-72. (Pubitemid 351156805)
51. French J, Gronseth G. Lost in a jungle of evidence: We need a compass. Neurology. 2008;71:1634-8.
52. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology. 2004;63:2104-10. (Pubitemid 39636259)
53. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebocontrolled trial. J Pain. 2005;6:253-60. (Pubitemid 40488803)
54. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A doubleblind, placebo-controlled trial. Pain. 2004;110:628-38. (Pubitemid 39036794)
55. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, doubleblind, multicentre, placebo-controlled trial of flexible-and fixeddose regimens. Pain. 2005;115:254-63. (Pubitemid 40725282)
56. Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
57. Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double-blind study. Eur J Pain. 2008;12:203-13. (Pubitemid 350180540)
58. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: Findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448-54.
59. Backonja M, Beydoun A. Edwards KRet al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA. 1998;280:1831-6. (Pubitemid 28544423)
60. Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: A placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66:251-2. (Pubitemid 29103537)
61. Wiffen PJ, McQuay HJ, Edwards J, Moore RA. WITHDRAWN: Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2011, Issue 3. Art. No. CD005452.
62. Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes: A randomized placebo controlled study. Acta Neurol Scand. 2002;106:248-52. (Pubitemid 35177990)
63. Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: A randomized double-blind placebocontrolled study. QJM. 2004;97:33-8. (Pubitemid 38195700)
64. Vrethem M, Boivie J, Arnqvist H, et al. A comparison of amitriptyline and maprotiline in the treatment of painful diabetic neuropathy in diabetics and nondiabetics. Clin J Pain. 1997;13:313-23. (Pubitemid 28028096)
65. Max MB. Endogenous monoamine analgesic systems: Amitriptyline in painful diabetic neuropathy. Anesth Prog. 1987;34: 123-7. (Pubitemid 17147404)
66. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37:589-96. (Pubitemid 17057933)
67. Mendel CM, Klein RF, Chappell DA, et al. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. JAMA. 1986;255:637-9. (Pubitemid 16160832)
68. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA. 1984;251:1727-30. (Pubitemid 14174179)
69. Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG, Gonzalez-Barranco J, Lozano-Castaneda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy: A double-blind cross-over study. Pain. 1985;23:395-400. (Pubitemid 16212853)
70. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-6.
71. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain. 1991;45:3-9.
72. Sindrup SH, Gram LF. Skjold Tet al.: Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol. 1990;30:683-91. (Pubitemid 20377596)
73. Raskin J, Pritchett L, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in themanagement of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-56. (Pubitemid 41727332)
74. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-18. (Pubitemid 40828506)
75. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-20. (Pubitemid 44632065)
76. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: Evidencebased findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29(Suppl):2536-46. (Pubitemid 350299457)
77. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A doubleblind, placebo-controlled study. Pain. 2004;110:697-706. (Pubitemid 39036802)
78. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001;3:53-62. (Pubitemid 33130299)
79. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology. 2003;60:1284-9. (Pubitemid 36460983)
80. Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial. Pain. 1999;83:85-90. (Pubitemid 29446160)
81. Freeman R, Raskin P, Hewitt D, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic neuropathy. Curr Med Res Opin. 2007;23:147-61. (Pubitemid 46191680)
82. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 2003;60:927-34. (Pubitemid 36348923)
83. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12:804-13.
84. Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care. 1992;15:8-14.
85. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehiclecontrolled study. Arch Intern Med. 1991;151:2225-9.
86. Scheffler N, Sheitel P, Lipton M. Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc. 1991;81:288-93.